New Research on PCA3 Presented at the 2013 European Association of Urology (EAU) Congress

PCA3 has an Established Place in the Diagnosis of Prostate Cancer

QUEBEC CITY, March 21, 2013 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR) is pleased to report that Dr. Harry Rittenhouse spoke about the clinical utility of the urinary marker PCA3 during the International Conference on Prostate Cancer Prevention 2013 with Consensus Conference on Chemoprevention of Prostate Cancer held during the 28th annual European Association of Urology (EAU) congress held in Milan from March 15-19th.

One of the goals of this day-long special session during the EAU congress was to discuss current management approaches to prostate cancer screening and hopefully come up with some consensus statements in early detection and prognostic biomarkers to predict high grade disease and the most appropriate clinical preventions. One of the session chairmen, Professor Powel Brown of M.D. Anderson Cancer Center in Houston, Texas, shared his hopes to see a strong message on the use of biomarkers for prognostic stratification of prostate cancer into low and high risk disease. For Dr. Jack A. Schalken, Professor of experimental urology at the Radboud University Nijmegen Medical Center (The Netherlands), there is no doubt that "PCA3 has an established place in the diagnosis of prostate cancer and is now also considered for follow-up use in chemoprevention studies".

In a separate thematic session where prostate cancer experts from both sides of the Atlantic discussed current work on candidate tumor markers for prostate cancer and the prospects for these biomarkers to serve as possible replacements for PSA-based diagnosis, presentations were given by Dr. Jack Groskopf (Hologic Gen-Probe, USA) who discussed urinary markers PCA3 and TMPRSS2-ERG, and Dr. Monique Roobol (Erasmus University Medical Center, The Netherlands) who provided insights on studies that examine reducing unnecessary biopsies for suspicion of prostate cancer.

The Annual EAU Congress is Europe's largest urology event and serves as a platform for the international urological community to share the latest and the most relevant knowledge with medical experts practicing across the board.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.

Forward‐looking statements

This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE: DiagnoCure inc.

For further information:

Investors 
DiagnoCure Inc. 
Chantal Miklosi 
Chief Financial Officer 
(418) 527-6100 
communications@diagnocure.com

Media
DiagnoCure Inc.
Geneviève Couture
Coordinator, Administration and Communications
(418) 527-6100
communications@diagnocure.com